Replies to post #197623 on Biotech Values

[caravon]

I wasted 30 min listening to ENTA's conference call.

Q&A session was a total waste since ENTA's management was evasive answering any question and promising to provide some future clarification.

As regarding to their future pipeline development, there are no indications of potential markets they intend to address. It appears they operate like an academia rather than a commercial company. No wonder than ENTA share prices are in a dog house.

[jbog]

During FY4Q15 (which predates any ABBV HCV sales in Japan), ENTA received V-Pak/Technivie/Viekirax royalties from ABBV at an annualized rate of $57M.

While these numbers might have some upside they certainly are dismal compared to the >$200m that was projected.

The market won't be there.

[DewDiligence]

ABBV/ENTA—FDA accepts NDA for qD formulation of V-Pak for review:

http://finance.yahoo.com/news/abbvie-announces-fda-acceptance-drug-130000460.html

The difference between the qD formulation of V-Pak and regular V-Pak is that the qD formulation includes an extended-release version of dasabuvir (a/k/a ABT-333, the non-nucleoside polymerase inhibitor).

The PDUFA date for this NDA should be on or about 10/2/16.

[DewDiligence]

ENTA FY1Q16 EPS=$1.36—cash*=$254.5:

http://finance.yahoo.com/news/enanta-pharmaceuticals-reports-financial-results-210200818.html

CC at 4:30pm ET.

*Includes $17.9M of royalties earned (but not yet received) from ABBV.